Tagrisso reduced the risk of disease recurrence in the brain by 82% in the adjuvant treatment of early-stage EGFR-mutated lung cancer
19 September 2020 17:30 BST Tagrisso reduced the risk of disease recurrence in the brain by 82%in the adjuvant treatment of early-stage EGFR-mutated lung cancer ADAURA Phase III trial data at ESMO reinforce the proven clinicalactivity of Tagrisso in treating central nervous system metastases Results from a prespecified exploratory analysis of the positive ADAURA Phase III trial showed AstraZeneca's Tagrisso (osimertinib) demonstrated a clinically meaningful improvement in central nervous system (CNS) disease-free survival (DFS) in the adjuvant treatment of patients with early-
Kojamo will celebrate the global Zero Emissions Day on 21 September 2020 by compensating the carbon dioxide emissions caused by the impacts of its employees’ work on the planet’s day off. It will do this by creating a new carbon sink in Finland through afforestation.Kojamo will participate in Zero Emissions Day 2020 by contributing to the afforestation of a new carbon sink in Finland. The carbon sink is large enough to cover the carbon dioxide emissions caused by all of Kojamo’s employees’ work during Zero Emissions Day. In addition, to mitigate climate change, Kojamo will plant more than
